[Current Clinical Practice Pattern for Castration-Resistant Prostate Cancer(CRPC)in Japan].
Gan To Kagaku Ryoho
; 48(11): 1359-1363, 2021 Nov.
Article
em Ja
| MEDLINE
| ID: mdl-34795127
ABSTRACT
Although various agents are reported against castration-resistant prostate cancer(CRPC), little is known about their actual clinical use in Japan. In this study, 484 patients diagnosed with CRPC during androgen-deprivation therapy were selected from Japan's leading multicenter collaborative research real-world database. The treatment details and prognosis were analyzed. It was observed that the castration treatment represented by the use of LH-RH agonists and antagonists was continued in almost all cases even after CRPC diagnosis. First-line non-castration agents for the CRPC treatment including certain novel agents approved from 2010 onwards and conventional agents used before that were selected for use in 76.5% and 23.5% of cases, respectively, with the 1-year continuation rates being 57.7%, and 52.4%, respectively. The 1.5-year overall survival rate from CRPC was 63.7%(90.0% in the conventional agents' group and 58.8% in the novel agents' group). Previously, conventional agents were sometimes selected for the CRPC treatment; hence, they still seemed to play a role in clinical practice in Japan.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias de Próstata Resistentes à Castração
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Humans
/
Male
País/Região como assunto:
Asia
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Ano de publicação:
2021
Tipo de documento:
Article